Dr. Yanhua Xie is also known as Jennifer Xie, the name she uses for almost all her publications. Xie received her Ph.D. degree from the University of Arizona in 2005 while working under the guidance of Dr. Frank Porreca, a world-renowned pain scientist, at the Department of Pharmacology and Toxicology in Tucson. Her dissertation research focused on chronic morphine induced hyperalgesia and its underlying mechanisms.

Following her doctoral work, Xie moved on to a post-doctoral position with Dr. Scott Sherman in the Department of Neurology at the University of Arizona. Her research there focused on a potential gene therapy for Parkinson’s Disease (PD) by manipulating the neuronal excitability of striatum via adenoviral vectors/adeno-associated viral vectors in rat models of PD using electrophysiological techniques and behavioral testing.

Two years later, she joined Neuromed Pharmaceuticals in collaboration with Drs. Frank Porreca and Terry Snutch. Her research focused on developing selective T-type calcium channel blockers (small molecule) as novel therapeutics for chronic pain and elucidating the mechanisms of different subtypes of calcium channel blockers in pain-relief. She tested more than 100 novel compounds in rat models of neuropathic pain and inflammatory pain within two years.

When Neuromed merged with another company in 2009, Dr. Xie rejoined Dr. Porreca’s laboratory to study the neural circuitry for the sensory and affective components of pain. She also coordinated all the industrial projects to provide drug screening services (similar to a contract research organization, CRO) for many pharmaceutical companies to determine the efficacy of a wide variety of novel compounds in relieving headache, neuropathic, cancer, arthritic, visceral and inflammatory pains in rodent models.

Dr. Xie has a new interest after she joined NYITCOM in dissecting the potential mechanisms through which osteopathic manipulative treatments (OMT) mitigate different types of chronic pain states in preclinical pain models as well as the discovery of the new drug targets for non-opioid analgesics.

Recent Projects/Research

  • Identifying new therapies, especially non-opioid molecules acting on novel targets, to relieve chronic pain in humans via preclinical tools in a wide variety of rodent pain models.
  • Elucidating the underlying mechanisms of the sensory and affective aspects of cephalic, neuropathic, inflammatory or cancer pain states and the potential mechanisms through which complementary therapies such as osteopathic manipulative treatments (OMT) or acupuncture relieve chronic pain.

Selected Publications

  • Sharma KD, Pandanaboina SC, Srivatsan M, Xie JY, Predominant differentiation of rat embryonic neural stem cells into functional oligodendrocytes. Neuroscience Letters, in press
  • Sharma KD, Schaal D, Kore RA, Hamzah RN, Pandanaboina SC, Hayar A, Griffin RJ, Srivatsan M, Reyna NS, Xie JY, Glioma-derived exosomes drive the differentiation of neural stem cells to astrocytes. PLOS ONE, in press
  • Chen Y, Moutal A, Navratilova E, Kopruszinski C, Yue X, Ikegami M, Chow M, Kanazawa L, Bellampalli SS, Xie J, Patwardhan A, Rice KC, Fields HL, Akopian A, Neugebauer V, Dodick D, Khanna R and Porreca F, A novel prolactin-mediated mechanism of nociceptor sensitization and opioid-induced hyperalgesia in females. Science Translational Medicine, 2020 Feb 5;12(529). pii: eaay7550.
  • Zhang H, Ramsey A, Xiao Y, Karki U, Xie JY, Xu J, Kelly T, Ono S, and Zhou G,  Dynamic phosphorylation and dephosphorylation 1 of CAP1 (Cyclase-Associated Protein 1) by antagonistic signaling through CDK5 and cAMP are critical for the protein functions in actin filament disassembly and cell adhesion. Molecular and Cellular Biology (cover story), 2020 Jan 30;40(4). pii: e00282-19
  • Xie JY, De Felice M, Kopruszinski CM, Eyde N, LaVigne J, Remeniuk B, Hernandez P, Yue X, Goshima N, Ossipov M, King T, Streicher JM, Navratilova E, Dodick D, Rosen H, Roberts E, and Porreca F, Kappa opioid receptor antagonists: a possible new class of therapeutics for migraine prevention. Cephalalgia, 37(8):780-794, 2017
  • Xie JY, Chew LA, Yang X, Wang Y, Qu C, Wang Y, Federici LM, Fitz SD, Ripsch MS, Due MR, Moutal A, Khanna M, White FA, Vanderah TW, Johnson PL, Porreca F, and Khanna R, Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential, Pain, 157(9):2124-40, 2016
  • Xie JY, Qu C, Patwardhan A, Ossipov MH, Navratilova E, Becerra L, Borsook D and Porreca F, Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy, Pain, 155 (8):1659-1666, 2014.
  • Navratilova E*, Xie JY* (co-first author), Okun A, Qu C, Eyde N, Ci S, Ossipov MH, King T, Fields HL and Porreca F, Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry, PNAS, 109:20709-13, 2012.

For additional publications, please go to Pubmed.

Contact Info